Our
News
Check back on a regualr basis
for futher updates.
VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology
VasoDynamics files UK patent for Radiotherapy-Induced Oral Mucositis (RIOM) Clinical Trial Methodology Establishes Intellectual Property protection for proprietary RIOM clinical trial design 22nd December 2022 -
VasoDynamics submits UK Clinical Trial Application for NG11-2
VasoDynamics submits UK Clinical Trial Application for NG11-2 A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in
VasoDynamics establishes Clinical and Scientific Advisory Board
VasoDynamics establishes Clinical and Scientific Advisory Board Leading cancer research and treatment experts join our journey to tackle the debilitating side effects of cancer therapies 30th
VasoDynamics selects clinical trial sites across the UK and appoints Chief Investigator
VasoDynamics selects clinical trial sites across the UK and appoints Chief Investigator 30th June 2022 - VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention
VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production
VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production Platform Intellectual Property protection extended to 2042 5th March 2022 - VasoDynamics Ltd, the pharmaceutical
VasoDynamics strengthens Board and management team with key appointments
VasoDynamics strengthens Board and management team with key appointments Building a strong team of industry experts as clinical programmes progress • Paul Stainer, Director and Chief